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Abstract 
Purpose	of	review:	Systemic	lupus	erythematosus	(SLE)	is	caused	by	a	combination	of	genetic	and	acquired	
immuno-deficiencies	and	environmental	factors	including	infections.	An	association	to	Epstein-Barr	virus	
(EBV)	has	been	established	by	numerous	studies	over	the	past	decades.	Here,	we	review	recent	
experimental	studies	on	this,	and	present	our	integrated	theory	of	SLE	development.	
Recent	findings:	SLE	patients	have	dysfunctional	control	of	EBV	infection	resulting	in	frequent	reactivations	
and	disease	progression.	These	comprise	impaired	functions	of	EBV-specific	T-cells	with	an	inverse	
correlation	to	disease	activity	and	elevated	serum	levels	of	antibodies	against	lytic	cycle	EBV	antigens.	The	
presence	of	EBV	proteins	in	renal	tissue	from	SLE	patients	with	nephritis	indicates	a	direct	involvement	of	
EBV	in	SLE	development.	As	expected	for	patients	with	immuno-deficiencies,	studies	reveal	that	SLE	
patients	show	dysfunctional	responses	to	other	viruses	as	well.	An	association	to	EBV	infection	has	also	
been	demonstrated	for	other	autoimmune	diseases	including	Sjögren’s	syndrome,	rheumatoid	arthritis,	
and	multiple	sclerosis.	
Summary:	Collectively,	the	interplay	between	an	impaired	immune	system	and	the	cumulative	effects	of	
EBV	and	other	viruses	results	in	frequent	reactivations	of	EBV	and	enhanced	cell	death,	causing	
development	of	SLE	and	concomitant	autoreactivities.	
Keywords:	EBV,	infections,	immuno-deficiencies,	SLE	
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Introduction 
Systemic	lupus	erythematosus	(SLE)	is	an	autoimmune	rheumatic	disease	with	female	predominance	[1].	
Symptoms	include	rash,	oral	ulcers,	arthritis,	serositis,	renal	complications,	hematologic	and	immunological	
disorders	including	production	of	autoantibodies	against	nuclear	components	(anti-dsDNA,	anti-Sm,	anti-
histone,	anti-ribonucleoprotein)	(Table	1)	[2].		
The	disease	activity	typically	varies	with	periods	of	disease	flares	alternating	with	remissions.	Known	
predisposing	congenital	and/or	acquired	immuno-deficiencies	comprise	complement	deficiencies	
(especially,	C1q	and	C4),	impaired	cytokine	regulation,	T-cell	proliferation	and	B-cell	functions	including	
altered	immunoglobulin	production	(Table	1)	[1,4,5].	Together	with	external	factors,	predominantly	
infections,	development	of	SLE	is	elicited.	
Epstein-Barr	virus	(EBV)	latently	infects	the	majority	of	the	world’s	population	[6]	(Figure	1,	Table	2).	
Primary	infection	commonly	takes	place	during	childhood,	causing	a	mild	or	asymptomatic	infection.	
However,	30-70%	of	individuals	acquiring	a	primary	EBV	infection	during	adolescence	develop	infectious	
mononucleosis	(IM)	[10]	with	symptoms	resembling	those	of	SLE	[11,12,13].	Following	primary	infection,	
EBV	persists	in	a	latent	form	in	memory	B-cells,	evading	the	host’s	immune	system	and	preventing	
apoptosis	of	the	infected	cells	[8].	Occasionally,	EBV	reactivates	leading	to	expression	of	lytic	genes	and	
replication	of	the	viral	genome	resulting	in	production	and	release	of	new	infectious	virus,	which	can	infect	
epithelial-,	B-,	T-	and	NK-cells	(reviewed	in	[8,9]).		Also	in	the	lytic	cycle,	EBV	has	effective	immune	evasion	
strategies	including	expression	of	proteins	with	anti-apoptotic,	immuno-modulating	and	concealing	
functions	(reviewed	in	[9]).		
Various	mechanisms	have	been	proposed	for	activation	of	autoreactive	lymphocytes	caused	by	infections	
including	molecular	mimicry,	bystander	activation	and	superantigen	activation	(reviewed	in	[14]).	However,	
none	of	these	fully	explain	all	aspects	of	SLE	etiology.	
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EBV in SLE 
EBV	has	for	decades	been	suspected	to	be	an	environmental	agent	in	the	development	of	SLE	and	an	
association	is	by	now	widely	accepted.	An	altered	infection	pattern	with	poor	control	of	the	latent	EBV	
infection	and	exacerbations	of	an	active	lytic	cycle	has	been	established.	Previous	findings	comprise	high	
viral	loads,	increased	EBV	mRNA	expression,	and	elevated	humoral	responses	against	EBV	(reviewed	in	
[11,15,16]).	Already	in	1971	an	association	was	demonstrated	by	increased	EBV	antibody	titres	in	SLE	
patients	[15,17].	Numerous	studies	confirmed	higher	frequencies	and	elevated	titres	of	EBV-directed	
antibodies,	against	lytic	cycle	antigens,	in	SLE	patients	compared	to	healthy	controls	(HCs),	indicating	
frequent	EBV	reactivations	(reviewed	in	[11,18]).	These	findings	were	again	confirmed	recently	in	two	
studies.	Rasmussen	et	al.	examined	antibodies	to	EBV	early	antigen	diffuse	(EA/D)	in	plasma	samples	from	
77	SLE	patients	and	29	HCs	showing	significantly	higher	titres	of	both	IgM,	IgA	and	IgG	anti-EA/D	in	SLE	
patients	compared	to	HCs	with	no	association	with	immunosuppressant	intake	[19*].	Presumably,	these	
results	can	be	explained	as	the	host’s	attempt	to	control	widespread	lytic	infection	in	both	B-	and	epithelial	
cells	giving	rise	to	the	various	antibody	isotypes.	Results	of	Fattal	et	al.	confirm	the	findings	on	elevated	
anti-EA/D	IgG	together	with	increased	titres	of	anti-EBV-p23	IgG	in	49	SLE	patients	compared	to	23	HCs	
[20*].		
Westergaard	et	al.	found	normal	levels	of	both	IgM,	IgA	and	IgG	anti-EBNA1	by	investigating	28	SLE	
patients.	[21*].	Similarly,	Fattal	et	al.	recorded	a	decrease	in	EBNA1	antibody	titres	in	some	SLE	patients	
[20*].	These	findings	suggests	that	the	altered	humoral	immune	response	to	EBV	in	SLE	patients	primarily	
entails	the	lytic	cycle.	
An	association	between	lupus	nephritis	(LN)	and	the	EBV	antigen	latent	membrane	protein	(LMP)1	has	
been	shown	in	two	studies.	LMP1	on	EBV-infected	B-cells	mimics	the	signal	that	otherwise	is	generated	by	
the	CD40	pathway	in	CD4+	T-cell	help.	Yu	et	al.	detected	a	significantly	higher	positive	rate	of	both	LMP1	
and	EBV-encoded	RNA	(EBER)1	by	investigating	renal	tissue	from	58	LN	patients	compared	to	controls,	
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which	was	not	associated	with	immunosuppressant	medication,	age	or	concurrent	other	infection	[22**].	
Ding	et	al.	confirmed	these	findings	in	renal	tissue	from	51	young	(6-16	years)	SLE	patients	with	LN,	and	
furthermore	showed	a	positive	correlation	between	LMP1	and	the	classification	of	LN	suggesting	that	renal	
EBV-infection	may	be	directly	involved	in	the	development	of	LN	[23*].		
The	latent	state	EBV-antigen	LMP2A	(that	serves	as	a	survival	signal	that	normally	is	generated	by	antigen	
binding	to	the	B-cell	receptor)	was	recently	demonstrated	to	be	an	important	mediator	of	SLE	in	a	mouse	
model	[24**].	To	mimic	LMP2A	expression	in	EBV-infected	human	B-cells,	they	used	a	system	with	
conditional	expression	of	LMP2A	in	B-cells.	This	resulted	in	B-cell	hyperactivity	and	differentiation	into	
plasma	cells	producing	low-affinity	antibodies	and	most	interesting,	it	led	to	SLE-like	symptoms	including	
production	of	anti-dsDNA,	anti-cardiolipin	and	development	of	glomerulonephritis-resembling	lesions	
[24**].		
Previous	studies	have	demonstrated	that	SLE	patients	have	impaired	EBV-specific	T-cell	responses	
(reviewed	in	[9]).	We	have	recently	further	evaluated	these	responses	by	ex	vivo	stimulation	of	whole	blood	
samples	from	28	SLE	patients	compared	to	28	sex-	and	age-matched	HCs.	Results	showed	significantly	
fewer	CD8+	and	CD4+	T-cells	responding	to	EBNA1	and	EA/D	by	quantification	of	the	surface	activation	
marker	CD69	and	the	production	of	interferon	(IFN)γ	by	flow	cytometry	[25**].	Interestingly,	an	inverse	
association	between	EBV-specific	T-cells	and	production	of	EBV-directed	antibodies	was	observed,	and	
disease	activity	was	inversely	correlated	with	the	number	of	EA/D-specific	T-cells.	As	cell-mediated	
immunity	is	crucial	in	order	to	control	latent	EBV	infection,	these	results	suggest	impaired	control	of	EBV	in	
SLE	patients	with	a	shift	towards	more	frequent	reactivations	and	a	humoral	immune	response	attempting	
to	control	EBV	activity.	This	impaired	EBV	control	seems	to	contribute	to	the	exacerbation	of	SLE	disease	
symptoms	[25**].				
The	decreased	control	of	EBV	in	SLE	patients	was	also	lately	demonstrated	by	the	presence	of	EBV	DNA	
detected	by	PCR	in	serum	from	SLE	patients	[26],	and	by	several	case	reports.	A	50-year-old	woman	
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diagnosed	with	SLE	(and	concurrent	autoimmune	hepatitis)	developed	chronic	active	EBV	infection	with	
EBER-positive	lymphocytes	found	in	both	liver	and	gastric	mucosal	biopsies	and	in	high	concentrations	in	
the	CD4+	T-cells	in	the	blood	[27].	Similarly,	an	86-year-old	woman	with	SLE	developed	a	rare	form	of	EBV-
positive	plasmablastic	lymphoma	in	the	colon	[28].	Additionally,	two	case	reports	described	how	EBV-
positive	lymphoproliferative	disorders	can	be	initially	misdiagnosed	as	a	type	of	lupus	since	symptoms	
overlap	and	can	entail	the	presence	of	antinuclear	antibodies	[29,30].		
Other viruses in SLE 
Other	infectious	agents	especially	other	human	herpes	viruses	(HHVs)	have	been	associated	with	SLE	
including	cytomegalovirus	(CMV)	and	Varicella-zoster	virus	(VZV),	and	recent	studies	have	confirmed	this	
link.	Rasmussen	et	al.	showed	elevated	titres	of	IgG	and	IgA	antibodies	against	the	lytic	cycle	CMV	antigen	
pp52	in	SLE	patients	(n=77)	compared	to	HCs	(n=29),	but	not	to	the	lytic	cycle	HHV6	antigen	p41,	indicating	
that	not	all	anti-HHV	responses	are	dysfunctional	in	SLE	patients	[19*].	Chen	et	al.	demonstrated	a	
significantly	increased	positivity	of	UL55	expression	(coding	for	CMV	envelope	glycoprotein	gB)	in	
peripheral	blood	mononuclear	cells	(PBMCs)	from	60	SLE	patients	compared	to	111	HCs	and	also	increased	
titres	of	both	IgM	and	IgG	CMV	antibodies	[31*].	
Moreover,	both	an	increased	humoral	response	(elevated	levels	of	IgG	anti-gpVZV)	and	a	decreased	cell-
mediated	response	(lower	frequency	of	IFNγ-producing	PBMCs	and	decreased	CD4+	T-cell	proliferation	
upon	stimulation)	to	VZV	have	recently	been	revealed	in	SLE	patients	compared	to	HCs	[32**].		
Finally,	parvovirus	B19,	transfusion-transmitted	virus	(TTV)	and	human	endogenous	retroviruses	(HERVs)	
[33,34]	have	also	been	associated	with	SLE	[14,15,35],	presumably	as	a	result	of	general	immuno-
deficiencies.	
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EBV in other autoimmune diseases 
EBV	has	been	associated	with	other	autoimmune	diseases	including	Sjögren’s	syndrome	(SS),	rheumatoid	
arthritis	(RA),	and	multiple	sclerosis	(MS),	all	of	which	(like	SLE)	are	believed	to	be	multifactorial	with	a	
genetic	susceptibility	combined	with	environmental	triggers,	and	are	characterized	by	partly	overlapping	
symptoms	and	autoantibodies.		
SS	can	present	both	as	a	primary	and	secondary	disease	(often	associated	with	SLE	or	RA)	and	is	mainly	
characterized	by	disorders	of	the	exocrine	glands	[36].	RA	is	the	most	common	of	these	diseases	and	
symptoms	especially	comprise	arthritis	[37].	MS	is	an	autoimmune	disorder	in	the	central	nervous	system	
(CNS)	with	chronic	inflammatory	demyelinating	conditions	[38].	
Two	recent	papers	have	extended	the	knowledge	on	the	association	between	EBV	infection	and	SS.	Croia	et	
al.	focused	on	specific	lymphoid	structures	in	the	salivary	glands	of	SS	patients	and	observed	both	latent	
(LMP2A-positive)	and	lytic	(BFRF1-positive)	EBV-infected	memory	B-cells	and	plasma	cells,	respectively.	
Furthermore,	it	was	revealed	that	especially	Ro52-specific	antibody-producing	plasma	cells	were	infected	
with	EBV	[39**].	Kivity	et	al.	investigated	82	SS	patients	and	139	HCs	and	found	increased	positivity	of	EBV-
EA	IgG	in	SS	patients	which	correlated	with	the	presence	of	anti-Ro/SSA	and	anti-La/SSB,	indicating	a	
connection	between	EBV	reactivation	and	development	of	SS	[40*].		
Interestingly,	Westergaard	et	al.	found	that	the	immune	response	to	the	latent	stage	EBNA1	was	altered	in	
RA	patients	(n=77)	with	highly	increased	titres	of	EBNA1	antibodies	of	both	IgM,	IgG	and	IgA	isotypes	
compared	to	both	HCs	(n=28)	and	SLE	patients	(n=28).	The	EBNA1	IgM	and	IgA	were	furthermore	found	to	
associate	with	presence	of	rheumatoid	factors	IgM	and	IgA,	respectively,	indicating	a	direct	connection	
between	development	of	these	autoantibodies	and	the	altered	immune	response	to	the	latent	EBV	
infection	[21*].	In	addition,	Cornillet	et	al.	demonstrated	an	association	between	antibodies	to	a	
citrullinated	EBNA1	peptide	and	antibodies	against	other	characteristically	citrullinated	peptides	in	RA	
patients	[41].	The	altered	immune	response	to	EBV	in	RA	patients	was	also	demonstrated	by	Erre	et	al.,	by	
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showing	increased	EBV	DNA	positivity	and	load	in	PBMCs	from	77	RA	patients	compared	to	58	HCs	and	
increased	prevalence	of	both	EBNA1	IgG	and	EBV-EA	IgG	[42].		
The	role	of	EBV	in	MS	development	has	for	long	been	investigated.	A	characteristic	(although	not	specific)	
feature	of	MS	is	the	intrathecal	production	of	antibodies	(oligoclonal	bands)	[38].	This	presumably	reflects	
the	presence	of	EBV-infected	B-cells	in	the	CNS,	in	line	with	a	theory	of	entry	of	EBV-specific	T-cells	into	
CNS	causing	attacks	(reviewed	in	[43]).	Actually,	Nierop	et	al.	recently	demonstrated	increased	frequencies	
of	intrathecal	T-cell	reactivity	in	MS	patients	using	peripheral	autologous	EBV-infected	B-cells	as	antigen-
presenting	cells	[44*].	An	uncontrolled	latent	EBV	infection	was	also	established	by	Nejati	et	al.	with	a	
significantly	higher	EBV	DNA	load	in	PBMCs	from	MS	patients	compared	to	HCs,	which	was	inversely	
associated	with	vitamin	D	concentrations,	suggesting	a	vitamin	D	contribution	to	the	immune-modulation	
of	EBV	in	MS	patients	[45*].	The	altered	immune	reaction	to	EBV	in	MS	patients	also	entails	elevated	EBV	
antibody	titres	[45*,46,47,48,49**].		
Discussion: The role of EBV and other viruses in the etiology of SLE and other autoimmune 
diseases 
EBV	is	an	important,	extremely	successful	HHV,	which	infects	essentially	all	of	mankind	(Figure	1,	Table	2).	
However,	this	fact	is	also	a	common	objection	to	EBV	having	a	causative	role	in	SLE	and	other	autoimmune	
diseases.	A	related	question	is	how	EBV	can	cause	several	seemingly	different	autoimmune	diseases.	These	
questions	can	simply	be	answered	by	the	role	of	individual	genetically	determined	immuno-profiles	and	by	
individual	combinations	of	infections,	environmentally	induced	immunosuppressions,	viral	reactivations	
and	treatment	regimes	(Figure	2).		
EBV	infects	epithelial	cells	and	other	cell	types	and	it	affects	the	immune	system	of	the	host	directly	by	
infection	of	lymphocytes	with	subsequent	immortalization	and	indirectly	by	expression	of	immuno-
modulating	viral	antigens.	EBV	infection	may	develop	diverse	autoreactivities	in	different	individuals	
according	to	genetic	susceptibility	and	immune	condition	(Table	1),	the	types	of	infected	cells,	the	sites	of	
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reactivation	and	immune	responses	against	EBV	and	in	this	way	be	a	contributive	agent	to	diverse	yet	
overlapping	autoimmune	diseases.	
An	apparent	paradox	is	how	current	treatment,	based	on	immunosuppression,	can	be	successful	against	a	
virus-induced	autoimmune	disease	like	SLE.	This	paradox	may	be	resolved	by	the	biology	of	EBV,	its	tropism	
for	B-cells	and	the	ability	of	immunosuppression	to	limit	the	spreading	of	EBV	and	infected	B-cells	in	
addition	to	its	dampening	of	inflammation.	This	is	supported	by	the	ability	of	anti-CD20	drugs	to	control	
disease	activity	[50].	
Conclusion 
In	our	opinion,	the	evidence	for	a	causative	role	of	EBV	in	SLE	and	other	autoimmune	diseases	is	so	
compelling,	that	future	research	should	be	focused	on	the	additional	role(s)	of	other	(herpes)viruses	and	
possible	new	therapies	based	on	immuno-modulation	and/or	anti-viral	drugs.	Currently,	there	is	an	
aggravating	scarcity	of	vaccines	and	drugs	with	efficacy	against	EBV.	
	
Key points: 
• SLE	patients	have	characteristic	immuno-deficiencies	
• EBV	infects	SLE	patients,	which	cannot	control	the	virus	effectively	
• EBV	evades	the	immune	system	and	can	switch	between	latent	and	lytic	life	stages	
• Repeated	reactivations	of	EBV	causes	SLE	disease	flares	and	associated	autoimmune	manifestations	
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Figure legends 
Table 1.  SLE characteristics [2] and predisposing immuno-deficiencies [1,3,4] 
Table 2.  EBV characteristics and associated diseases [7,8,9] 
Figure 1. Epstein Barr virus 
EBV	 consists	 of	 a	 dsDNA	 genome	within	 a	 capsid	 surrounded	 by	 tegument	within	 a	 lipid	 envelope	with	
surface	 glycoproteins.	 EBV	 is	 transmitted	 via	 saliva	 and	 enters	 epithelial	 cells	 and	 B-cells.	 EBV	 shifts	
between	a	resting	latent	state	in	memory	B-cells	with	a	limited	expression	of	genes	(EBNAs	and	LMPs)	and	
reactivation	to	lytic	cycle	with	expression	of	immediate	early	(IE)	antigens	(transcription	factors),	early	(E)	
antigens	 (including	 EBV-EA/D)	 and	 replication	 of	 the	 viral	 genome	 and	 subsequent	 expression	 of	 late	 (L)	
antigens	 (structural	 proteins	 including	 EBV-p23)	 resulting	 in	 production	 and	 release	 of	 new	 virus.	 [7,8]	
(electronmicrograph:	http://www.sciencedaily.com/releases/2005/07/050725065240.htm)	
Figure 2. Gene – environment interactions in the development of SLE with an emphasis on the 
role of EBV 
Timeline	 showing	 the	 immuno-profile	 and	 environmental	 elements	 affecting	 the	 development	 of	 SLE	 in	
genetically	predisposed	individuals	with	certain	immuno-deficiencies.	The	primary	infection	with	EBV	leads	
to	 production	 of	 EBV-directed	 antibodies	 and	 generation	 of	 EBV-specific	 T-cells.	 Over	 time	 (and	 with	
multiple	 reactivations)	 the	 quantity	 of	 EBV-specific	 T-cells	 decreases	 and	 the	 latent	 infection	 gets	 even	
harder	 to	 control	 resulting	 in	 increasing	 number	 of	 disseminated	 EBV-infected	 cells	 and	 eventually	
production	 of	 autoantibodies	 triggered	 by	 the	 cumulative	 waste	 load	 and	 further	 development	 of	 SLE	
symptoms.	 The	 EBV-specific	 antibodies	 stay	 at	 high	 titres	 reflecting	 the	 increased	 antigen	 load	 and	
attempts	to	control	the	numerous	reactivations	as	compensation	for	lack	of	cell-mediated	control.		
	
